NCT07145502View on ClinicalTrials.gov

Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes

Active, not recruitingOBSERVATIONAL
Enrollment

76

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

July 15, 2024

Study Completion Date

September 19, 2027

Conditions
Autoimmune EncephalitisEarly-stage PanencephalitisNeuroinflammatory Demyelination
Interventions
BIOLOGICAL

Allogeneic MSC infusions (IV)

Optional T-reg therapy (experimental/compassionate-use basis)

Trial Locations (1)

01-234

Biocells Medical, Warsaw

Sponsors

Lead Sponsor

Biocells Medical
All Listed Sponsors
lead

Biocells Medical

INDUSTRY